#3 Neurodegeneration: glymphatic system, SMA

Overview of Motor Neuron Disease

• The current session focuses specifically on Spinal Muscular Atrophy (SMA), serving as the concluding part of a comprehensive series that has extensively covered various motor neuron diseases. This series has meticulously discussed the intricate pathology, the underlying genetic bases, and identified crucial drug targets for devastating conditions such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

• Previous lectures established a foundational understanding of these neurodegenerative disorders, emphasizing the complex interplay of genetic predispositions, molecular abnormalities, and cellular dysfunction that contribute to their progression. The overarching goal is to understand how these diseases manifest and how therapeutic strategies can be developed to counteract their effects.

Pathological Findings

• A prominent and frequently observed hallmark across many motor neuron diseases, including ALS and FTD, is the presence of ubiquitin inclusions. These inclusions are typically composed of misfolded proteins, such as TDP-43 (TAR DNA-binding protein 43) or FUS (Fused in Sarcoma), which aggregate uncontrollably within neurons. These aggregates signify widespread proteinopathy, a condition characterized by the abnormal accumulation and aggregation of proteins, and indicate severely impaired protein clearance mechanisms within affected cells, leading to cellular stress and eventual death.

• Genetic investigations frequently yield overlapping results from Genome-Wide Association Studies (GWAS) for ALS and FTD. This strong genetic correlation suggests a shared genetic architecture and common pathogenic pathways underpinning these two seemingly distinct clinical entities. The implication is that ALS and FTD often exist on a clinical and molecular spectrum, with shared genetic risk factors contributing to their development and progression.

• It is of critical importance to understand the specific functions of individual genes that have been conclusively linked to the etiology of these complex diseases. Insights into these gene functions provide a window into the initial pathogenic processes at a molecular level, allowing researchers to pinpoint the earliest defects and subsequently identify precise and effective therapeutic targets.

Molecular Insights

• A significant role in neurodegeneration is played by excessive radicals and reactive oxygen species (ROS), which lead to severe oxidative stress. This oxidative stress damages critical cellular components, including lipids, proteins, and DNA, thereby accelerating neuronal dysfunction and disease progression. The generation of ROS can arise from various cellular metabolic processes and imbalances in antioxidant defenses.

• The concept of excitotoxicity is also a key mechanism in neuronal damage, primarily mediated by an overabundance of the neurotransmitter glutamate. Excessive glutamate stimulation of neuronal receptors, particularly NMDA receptors, leads to an overload of intracellular calcium, triggering a cascade of detrimental events that result in excessive neuronal stimulation and subsequent cellular death. This mechanism is a target for some current medications used in neurodegenerative diseases, for instance, riluzole for ALS, which reduces glutamate release.

• Strong emphasis is placed on pinpointing where disease mechanisms initially originate. Foundational insights gained through comprehensive genetic studies are particularly vital, as they often reveal the earliest molecular defects and provide crucial understanding into the fundamental causes of disease onset, rather than merely observing downstream effects.

Introduction to the Lymphatic System

• Modern research has led to the relatively recent discovery of a specialized lymphatic system within the brain, termed the glymphatic system, which is crucial for waste clearance and maintaining brain homeostasis. This system was largely unacknowledged until comprehensive studies elucidated its function.

• The pivotal discovery regarding the glymphatic system originated from the ground-breaking work by Dr. Maiken Nedergaard's group. Their simple yet profound experiment involved introducing tracer dyes, such as dextrans or fluorescent albumin, into the cerebrospinal fluid (CSF) of rodent brains. They observed that these dyes diffused far more easily and extensively into the brain parenchyma during sleep states compared to wakefulness.

  • This observation quantitatively demonstrated a significant increase in the interstitial space (the space between cells) in the brain during sleep. The increased space facilitated a significantly better and more efficient waste clearance from the brain during sleep, unraveling a critical biological process essential for brain maintenance and health.

• The explanation for this enhanced clearance lies in the shrinking of glial cells, specifically astrocytes, during sleep. This cellular contraction leads to a substantial increase in the interstitial space, thereby making more room for the interstitial fluid (ISF) to flow more efficiently throughout the brain parenchyma.

• This enhanced fluid movement forms a robust mechanism that actively transports toxic molecules and metabolic waste products, such as amyloid-beta (implicated in Alzheimer's disease) and tau proteins (implicated in various tauopathies including FTD), out of the brain. These waste products are then drained into the peripheral lymphatic system.

• This research underscores the paramount importance of adequate sleep in facilitating this glymphatic waste removal from the brain. Consequently, chronic sleep disruption is directly linked to the potential detrimental accumulation of neurotoxic substances, strongly implicated in the pathogenesis of various neurodegenerative diseases.

Perivascular Space and Brain Vasculature

• A detailed explanation of the unique blood vessel structure and function within the brain is critical, particularly focusing on microvessels (capillaries and arterioles). Unlike peripheral vessels, brain microvessels largely lack smooth muscle cells in their walls and are intricately and closely enveloped by astrocytic end-feet. These astrocytic end-feet are not merely supportive but are critical components for maintaining blood-brain barrier integrity and regulating glymphatic flow.

• Astrocytic end-feet meticulously wrap around brain blood vessels, forming the crucial perivascular space, also widely known as the Virchow-Robin space. This anatomical arrangement is fundamental to the glymphatic system's function.

  • A key component of this system is aquaporin-4 (AQP4) water channels, which are predominantly located on the astrocytic end-feet juxtaposed directly to the perivascular space. These channels are vital for facilitating dynamic water movement and the rapid exchange of glymphatic fluid across the astrocytic membrane. Dysregulation or mislocalization of AQP4 is increasingly implicated in the pathology of various neurodegenerative diseases, affecting the efficiency of waste clearance.

• Reaffirming glymphatic flow as the primary mechanism for the effective clearance of metabolic waste products from the brain, it is established that this process is significantly enhanced during periods of sleep, correlating with the earlier described experimental findings.

• It is proposed that the potential impact of insufficient cerebral perfusion (reduced blood flow) and impaired glymphatic clearance could collectively lead to the detrimental accumulation of neurotoxic proteins. This chronic buildup would significantly contribute to the pathogenesis and progression of neurodegenerative diseases like ALS and FTD, highlighting the interconnectedness of vascular and waste clearance systems in brain health.

Clinical Manifestations of Spinal Muscular Atrophy (SMA)

• SMA is defined and characterized as a severe, often early-onset, genetic motor neuron disease. It is clinically marked by progressive muscle weakness and profound atrophy, directly resulting from the loss of alpha motor neurons in the spinal cord and brainstem. These motor neurons are responsible for transmitting signals from the brain to the muscles, so their degeneration leads to impaired muscle function.

• The genetic understanding of SMA confirms an autosomal recessive inheritance pattern. This means that for an individual to be affected by SMA, they must inherit two copies of the mutated gene—one from each carrier parent. While both parents are typically asymptomatic carriers, the carrier frequency is significant, estimated at approximately 1 in 40 to 1 in 60 individuals in the general population. Despite this relatively high carrier frequency, symptomatic births are rarer, occurring in about 1 in 11,000 live births, due to the recessive nature of the inheritance.

• The disease is characterized by progressive muscle atrophy that leads to severe disability and the loss of critical motor function, impacting daily activities like sitting, walking, and breathing. In its most severe forms, SMA has a high mortality rate; for example, over $60\%$ of Type I SMA patients, without treatment, typically die before age 6, primarily due to severe respiratory failure caused by weakness of the diaphragm and intercostal muscles.

• The disease presents in four distinct clinical types, categorized primarily based on their severity and the age of symptom onset:

  • Type I (Werdnig-Hoffmann disease): This is the most severe and rapidly progressive form, with symptom onset typically occurring before 6 months of age, often evident at birth. Infants present with profound hypotonia (floppy baby syndrome), significant feeding difficulties, a weak cry, and never achieve the ability to sit independently. Respiratory involvement is severe and often life-threatening.

  • Type II (Intermediate SMA): Onset generally occurs between 6 and 18 months of age. Patients with Type II SMA can typically sit independently for a period but usually cannot walk without assistance. They often require wheelchairs later in life and experience progressive muscle weakness and respiratory compromise, though less severe than Type I.

  • Type III (Kugelberg-Welander disease): This is a milder form compared to Types I and II, with onset typically occurring after 18 months of age, often in childhood or adolescence. Patients can walk independently at some point, but they may lose this ability later in life, often in adulthood, due to progressive muscle weakness. Respiratory involvement is usually less severe.

  • Type IV (Adult-Onset SMA): Representing the mildest form, this type typically manifests with symptom onset in adulthood, often after the age of 30. It is characterized by mild to moderate muscle weakness, usually affecting proximal muscles, and progresses slowly. It typically does not significantly impact life expectancy.

Genetic Basis of SMA

• The primary genes involved in SMA are SMN1 (Survival of Motor Neuron 1) and SMN2 (Survival of Motor Neuron 2). Both genes are located in a complex region on chromosome 5q13, existing as inverted repeats.

  • SMN1: This gene is essential for normal motor neuron survival and function because it typically produces a full-length, highly functional SMN protein. This protein is crucial for the assembly of small nuclear ribonucleoproteins (snRNPs), which are integral components of the spliceosome, vital for proper RNA processing.

  • SMN2: This gene is a functionally non-essential paralog (a gene related by duplication in the genome) of SMN1 and can only partially compensate for the loss of SMN1. Due to a critical single nucleotide difference, specifically a C-to-T transition in exon 7, SMN2 predominantly produces a truncated, unstable, and largely non-functional form of the SMN protein by frequently skipping exon 7 during the pre-mRNA splicing process. The amount of full-length SMN protein produced by SMN2 is inversely correlated with disease severity; individuals with more copies of SMN2 tend to have milder forms of SMA, as more functional protein is generated.

Splicing Mechanism and Disease Impact

• The profound challenge in SMA pathology is posed by only six nucleotide differences between the SMN1 and SMN2 genes. Crucially, a single C-to-T transition within exon 7 of the SMN2 gene specifically disrupts an exonic splicing enhancer (ESE). This disruption leads to the frequent exclusion (skipping) of exon 7 during the pre-mRNA splicing process.

• It is critical to understand spliceosomal function, as the spliceosome is the highly complex molecular machinery composed of snRNPs and proteins responsible for accurately removing non-coding introns and precisely joining coding exons in messenger RNA (mRNA) precursors (pre-mRNA) to form mature mRNA. This mature mRNA then serves as the template for protein synthesis.

• The mutational effects, particularly the homozygous deletion or pathogenic mutation of SMN1, profoundly alter splicing patterns. This alteration causes the predominant production of a truncated SMN protein from SMN2, which directly lacks the C-terminal region crucial for its stability and function. This deficiency of full-length, functional SMN protein directly underlies the pathogenesis of SMA, leading to motor neuron degeneration.

Investigating SMN Functionality

• Experimental designs were instrumental in elucidating SMN functionality and the differential splicing of SMN1 and SMN2. A key approach involved the use of plasmid reporter constructs. These constructs, typically containing a minigene with either the SMN1 or SMN2 gene sequences (including exon 7 and flanking intronic regions) fused to a reporter (e.g., green fluorescent protein or luciferase), were transfected into cell lines.

  • Through comparative analysis of the reporter gene expression, researchers were able to examine and quantitatively measure the differential splicing behavior of SMN1 and SMN2. These experiments clearly demonstrated how specific genetic variations, particularly the C-to-T change in exon 7 of SMN2, dictate the inclusion or exclusion of exon 7. This direct observation provided irrefutable evidence for why SMN1 produces functional, full-length SMN protein while SMN2 predominantly produces the truncated, non-functional variant.

Potential Pharmacological Strategies

• Significant progress has been made in the successful development of pharmacological interventions designed to enhance the correct splicing of SMN2, thereby critically increasing the production of full-length, functional SMN protein. These therapies represent a paradigm shift in SMA treatment:

  • Nusinersen (Spinraza): This is an antisense oligonucleotide (ASO) therapy that is administered intrathecally (injected directly into the cerebrospinal fluid surrounding the spinal cord) every few months. Nusinersen specifically binds to an intronic splicing silencer (ISS) located within intron 7 of the SMN2 pre-mRNA. By binding to this silencer, Nusinersen blocks repressor proteins, thereby promoting the inclusion of exon 7 during splicing. This mechanism leads to a significant increase in the amount of full-length, functional SMN protein produced from the SMN2 gene.

  • Risdiplam (Evrysdi): This is a similar small molecule therapy, but notable for its oral administration, making it more convenient for patients. Risdiplam acts as an SMN2 splicing modifier by targeting splicing factors. It works by binding to a specific site on the SMN2 messenger RNA (pre-mRNA), which modifies the splicing process to promote the inclusion of exon 7. This increases systemic SMN protein production throughout the body, benefiting a wider range of tissues beyond motor neurons.

  • Gene therapy focused on SMN1 delivery (e.g., Onasemnogene abeparvovec or Zolgensma): This revolutionary approach is a one-time intravenous injection that utilizes an adeno-associated virus (AAV) vector specifically AAV9, which can cross the blood-brain barrier. The AAV9 vector delivers a functional copy of the SMN1 gene directly into affected motor neurons and other cells. This treatment aims to provide a permanent genetic correction by supplying the missing or dysfunctional SMN1 gene, allowing cells to produce the necessary full-length SMN protein. It is often highlighted for its efficiency and simplicity as a single treatment.

Conclusion and Future Implications

• The discussion strongly emphasized the profound significance of understanding gene splicing, the innovative potential of genetic therapy, and the strategic development of pharmacological interventions to effectively ameliorate Spinal Muscular Atrophy. These advancements represent a paradigm shift in treating this previously devastating and often fatal disease, transforming outcomes for affected individuals.

  • Speculation continues regarding the long-term effects and potential complications of these novel treatments. This is particularly crucial considering that SMA can affect tissues beyond just spinal motor neurons, impacting various organs such as the heart, gastrointestinal system, and skeletal muscle more broadly. Therefore, a holistic understanding of systemic SMN protein restoration and its effects on all affected tissues is necessary for comprehensive long-term care.

• A key research question remains in understanding the nuanced pharmacological impacts on broader cellular processes, such as microtubule transport dynamics, versus the upfront, targeted correction of underlying splicing issues. Investigating this relationship may reveal additional therapeutic avenues or challenges, potentially leading to combination therapies or more refined single-agent approaches.

Questions and Engagement

• An open floor for questions allowed for further in-depth understanding of complex splicing dynamics and their critical implications for the evolving landscape of SMA treatment strategies. These discussions aim to clarify the mechanisms of action and implications for patient care.

• The session concluded with a discussion of newer studies and ongoing, cutting-edge research into the intricate relationship between the glymphatic system and various neurodegenerative diseases. This emerging area of research is emphasizing the burgeoning importance of waste clearance mechanisms for future therapeutic developments across a spectrum of neurological disorders.